What is he best known for?
The fields of study he is best known for:
The scientist’s investigation covers issues in Antibody, Cancer research, Immunology, Molecular biology and CD20.
His studies deal with areas such as Computational biology, Antigen and Anti vegf as well as Antibody.
His work deals with themes such as T cell, Proto-Oncogene Proteins c-mdm2, Mdm2 and Cancer immunotherapy, which intersect with Cancer research.
His Molecular biology study incorporates themes from Protein structure, Biochemistry, Antigen binding and Bivalent.
The various areas that Christian Klein examines in his CD20 study include Monoclonal antibody, Antibody-dependent cell-mediated cytotoxicity and Rituximab.
His research integrates issues of Cell cycle, Nutlin and Growth inhibition, Cell growth in his study of Nuclear protein.
His most cited work include:
- In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. (3594 citations)
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity (643 citations)
- Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker. (542 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Antibody, Cancer research, Immunology, CD20 and T cell.
His Antibody research incorporates themes from Molecular biology, Receptor and Antigen.
His Cancer research research focuses on Cancer and how it connects with Combination therapy.
He specializes in Immunology, namely IL-2 receptor.
His study in CD20 is interdisciplinary in nature, drawing from both Pharmacology, Antibody-dependent cell-mediated cytotoxicity, B cell and Rituximab.
His research in T cell intersects with topics in Carcinoembryonic antigen, Tumor microenvironment, CD3, CD8 and Tumor antigen.
He most often published in these fields:
- Antibody (39.02%)
- Cancer research (32.77%)
- Immunology (18.94%)
What were the highlights of his more recent work (between 2017-2021)?
- Cancer research (32.77%)
- Antibody (39.02%)
- T cell (14.96%)
In recent papers he was focusing on the following fields of study:
Christian Klein mainly investigates Cancer research, Antibody, T cell, Obinutuzumab and Receptor.
His research on Cancer research also deals with topics like
- Immunotherapy which connect with Tumor microenvironment and In vivo,
- Cytotoxic T cell that connect with fields like Cancer cell,
- IL-2 receptor most often made with reference to CD8.
Christian Klein has researched Antibody in several fields, including Molecular biology and Cancer, Fibroblast activation protein, alpha.
Christian Klein interconnects Cytokine, B cell, Tumor antigen and Antigen in the investigation of issues within T cell.
His study focuses on the intersection of Receptor and fields such as Cell biology with connections in the field of Chimeric antigen receptor.
His biological study spans a wide range of topics, including Leukemia and Diffuse large B-cell lymphoma.
Between 2017 and 2021, his most popular works were:
- A transcriptionally and functionally distinct PD-1 + CD8 + T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade (284 citations)
- Climate change impact and adaptation for wheat protein (97 citations)
- Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. (66 citations)
In his most recent research, the most cited papers focused on:
His primary areas of investigation include Cancer research, Antibody, T cell, Obinutuzumab and Immunotherapy.
The study incorporates disciplines such as Cytotoxic T cell, Granzyme B, CD8, Receptor and In vivo in addition to Cancer research.
Christian Klein has included themes like Cell biology, Chimeric antigen receptor and Cytotoxicity in his Antibody study.
In his study, which falls under the umbrella issue of Chimeric antigen receptor, CD20 is strongly linked to Cancer cell.
His T cell study combines topics from a wide range of disciplines, such as Antigen and Cancer immunotherapy.
His Obinutuzumab research is multidisciplinary, incorporating elements of Venetoclax and Monoclonal.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
